Soros Fund Management LLC continued to hold its stake in shares of Zoetis Inc. (NYSE:ZTS) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 808,419 shares of the company’s stock at the end of the first quarter. Zoetis comprises about 0.9% of Soros Fund Management LLC’s investment portfolio, making the stock its 22nd largest position. Soros Fund Management LLC owned 0.16% of Zoetis worth $43,145,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of ZTS. Franklin Resources Inc. raised its stake in shares of Zoetis by 803.4% in the fourth quarter. Franklin Resources Inc. now owns 94,816 shares of the company’s stock valued at $5,076,000 after buying an additional 84,321 shares during the period. AQR Capital Management LLC raised its stake in shares of Zoetis by 20.3% in the fourth quarter. AQR Capital Management LLC now owns 93,103 shares of the company’s stock worth $4,984,000 after buying an additional 15,706 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Zoetis by 18.2% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,941 shares of the company’s stock worth $532,000 after buying an additional 1,530 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Zoetis during the fourth quarter worth about $6,257,000. Finally, Wealthfront Inc. raised its stake in shares of Zoetis by 14.8% in the fourth quarter. Wealthfront Inc. now owns 13,427 shares of the company’s stock worth $719,000 after buying an additional 1,731 shares during the period. Hedge funds and other institutional investors own 95.20% of the company’s stock.
Zoetis Inc. (ZTS) traded up 0.32% during midday trading on Friday, hitting $62.21. The stock had a trading volume of 1,540,607 shares. Zoetis Inc. has a one year low of $46.86 and a one year high of $63.85. The stock has a 50-day moving average price of $62.58 and a 200 day moving average price of $57.47. The firm has a market cap of $30.53 billion, a PE ratio of 36.17 and a beta of 1.03.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 4th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.05. The company had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.20 billion. Zoetis had a return on equity of 65.35% and a net margin of 17.25%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.48 EPS. On average, analysts predict that Zoetis Inc. will post $2.33 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Thursday, June 15th will be given a dividend of $0.105 per share. The ex-dividend date is Tuesday, June 13th. This represents a $0.42 dividend on an annualized basis and a yield of 0.68%. Zoetis’s dividend payout ratio (DPR) is presently 24.42%.
A number of brokerages have issued reports on ZTS. Cowen and Company set a $70.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. Deutsche Bank AG reissued a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Zoetis in a research report on Monday, July 17th. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research report on Tuesday, June 20th. Hilliard Lyons assumed coverage on Zoetis in a research report on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective for the company. Finally, Stifel Nicolaus reissued a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $63.47.
In other Zoetis news, insider Catherine A. Knupp sold 5,785 shares of the stock in a transaction on Friday, May 12th. The stock was sold at an average price of $60.16, for a total value of $348,025.60. Following the transaction, the insider now directly owns 24,415 shares in the company, valued at approximately $1,468,806.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.31% of the stock is owned by corporate insiders.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.